MSCI — MSCI Inc.

The July 21 post-earnings drop of ~10% on higher FY2026 opex guidance created a sour tape, but analyst sentiment has stayed firmly positive: consensus is Buy/Strong Buy with 20 buys vs 1 sell, and the average 12-month target of $701.71 still implies ~23% upside from $569.15. The Q2 index asset-based fee growth of +26.6% and stabilizing price action as of late August support a mildly bullish market tone.

Revenue has grown from $625.4M in Q3 2023 to $867.0M in Q2 2026, with YoY growth reaccelerating to roughly 12-14% in the last two reported quarters (Q1 2026 +14.1%, Q2 2026 +12.2%). Operating margins are also expanding: Q2 2026 operating margin was 56.2% versus 55.0% a year earlier, and Q1 2026 was 53.7% versus 50.6%. Q2 2026 diluted EPS rose to $4.70 from $3.92, and TTM free cash flow is about $1.57B. This is an upward inflection, not a one-quarter blip; the main blemish is management's raised opex guidance and faster-rising interest expense.

As of 2026-08-27, MSCI's trailing P/E is 31.3x, forward P/E is roughly 28.9x on FY2026E EPS of $19.72, and P/S is 12.4x. That compares to 5-year averages of 46.3x P/E and 18.0x P/S, so the stock is cheap relative to its own history. It is still an absolute premium multiple, but the PEG of 1.55 and reaccelerating growth make it look more reasonable than expensive.

At $569.15, the market is paying about 29x FY2026E EPS. If MSCI delivers the $19.72 estimate and holds a justified 33x multiple, fair value is ~$651; a partial re-rating back toward 40x would imply ~$789. The stock is not pricing in a major re-rating—it is pricing in cost pressure, higher rates, and leverage. Downside scenario: another opex miss plus weak asset-based fee growth could compress the multiple to ~25x, implying ~$493. The reward path is larger than the risk path if management holds its guidance.

As of 2026-08-27, RSI is 48.83, which is neutral—not oversold or overbought. Price is +0.45% above the 20-day SMA, but -1.79% below the 50-day and -0.71% below the 200-day, so the stock remains range-bound/consolidating after the July selloff. The 52-week range is $501.08-$644.77; a reclaim of the 50-day would be the first clear technical improvement, while a break below $501 would signal more downside.

• Global equity market levels and AUM directly drive MSCI's index asset-based fees; resilient equity markets are a tailwind.
• Rising interest rates increase MSCI's interest expense, which was already up ~48% YoY in Q2, and pressure the balance sheet with net leverage near 3.0x.
• The structural shift toward passive investing and index-based products supports recurring index fee growth.
• Regulatory and institutional demand for climate risk and private-market transparency data supports MSCI's product expansion.
• Sector rotation toward cheaper value and away from high-multiple financial-data names could keep MSCI's multiple compressed near term.

• Q3 2026 earnings (late October 2026): investors will focus on organic subscription growth reaccelerating and adherence to the $1.54B-$1.58B opex guidance.
• First Street climate-risk analytics cross-selling and the UBS private-markets partnership ramping up.
• November Semi-Annual Index Review and ongoing passive inflows tied to MSCI index rebalances; SGX futures/options launch could add derivative-related demand.
• If management tightens opex guidance later in 2026, the stock could re-rate quickly from current depressed multiples.

• Raised opex guidance may not be the last increase; recurring investment spending could keep margin expansion below expectations.
• Rising net leverage (~3.0x) and a BBB- credit profile leave less room for error, especially with interest expense up sharply.
• Index asset-based fees are sensitive to equity market declines, outflows, or volatility-driven AUM changes.
• Negative stockholders' equity from sustained buybacks makes the balance-sheet metrics look unusual and reduces financial flexibility.
• Acquisition integration (First Street) and product expansion could distract from core execution or fail to generate expected returns.

MSCI is a high-quality, wide-moat data/index franchise with ~83% gross margins, ~56% operating margins, reaccelerating revenue growth, and strong free cash flow, now available below its own historical valuation. The near-term expense and leverage increases are real, but they appear to be investment-led rather than structural deterioration; for a long-term-oriented investor, the current price offers an attractive risk/reward, though this is analysis, not personalized advice.

I calculated fair value by applying a justified 33x P/E to FY2026E EPS of $19.72, a premium multiple consistent with MSCI's recurring fee-based business, high margins, and secular growth, but well below its 5-year average P/E of 46.3x to reflect higher leverage, rising interest costs, and the raised opex guidance. 33 x $19.72 = ~$651.